Womed Leaf
Womed Sas · Decision date Aug 31, 2026
What did the FDA approve?
FDA records P240015/S002 as a supplement to PMA P240015, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 31, 2026.
FDA approval order statement
approval for changes to the manufacturing process and materials used to manufacture the plunger component of the inserter
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Aug 31, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P240015/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Womed Sas
- Product code
- MCN
- Decision code
- APPR
- Decision date
- Aug 31, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Barrier, absorbable, adhesion.
For the original device and its historical approval scope, see PMA P240015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240015 · Original PMA
Womed Leaf Resorbable Adhesion Barrier
P240015/S001 · Related supplement
Womed Leaf
P240015/S002 received
Application receipt date recorded by FDA.
P240015/S002 · FDA decision
Real-Time Process
P240015/S003 · Related supplement
Womed Leaf
Timeline entries are records held by MedtechLedger for P240015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Womed Sas | PMA approval | Sep 9, 2025 | FDA | |
Womed LeafP240015/S001 | Womed Sas | PMA supplement | Jan 28, 2026 | FDA |
Womed LeafP240015/S003 | Womed Sas | PMA supplement | Oct 25, 2026 | FDA |
Explore the linked device profile
Other records with product code MCN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S072 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Juveena Hydrogel SystemP250051/S001 | Rejoni, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Juveena Hydrogel SystemP250051 | Rejoni, Inc. | PMA approval | Sep 28, 2026 | FDA |
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S070 | ETHICON, Inc. | PMA supplement | Jun 25, 2026 | FDA |
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S069 | ETHICON, Inc. | PMA supplement | Jan 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Womed Sas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Batiment Balard Cit, 1919 Rte. De Mende, Montpellier, 34090
Sources and methodology
- Original FDA record: P240015/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


